| Lu, Esther |
NCT04966481: Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor |
|
|
| Recruiting | 3 | 81 | US | Palbociclib, Ibrance, Cetuximab, Erbitux | Washington University School of Medicine, Pfizer, The Joseph Sanchez Foundation | HPV-unrelated Head and Neck Squamous Cell Carcinoma | 02/27 | 02/27 | | |
NCT04412629: Cabozantinib in High Grade Neuroendocrine Neoplasms |
|
|
| Recruiting | 2 | 32 | US | Cabozantinib, Cabometyx, Blood for plasma biomarkers, Tissue biopsy | Washington University School of Medicine, Exelixis | High Grade Neuroendocrine Neoplasms | 07/25 | 03/26 | | |
NCT04831320: Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor |
|
|
| Active, not recruiting | 2 | 46 | US | nab-paclitaxel, Abraxane, Nivolumab, Opdivo | Washington University School of Medicine, Bristol-Myers Squibb | Metastatic Head-and-neck Squamous-cell Carcinoma | 12/25 | 09/26 | | |
NCT04852328: Three Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Positive Patients With Locally Advanced, HPV16-Positive Oropharyngeal Squamous-Cell Carcinoma |
|
|
| Recruiting | 2 | 30 | US | CUE-101 | Washington University School of Medicine, Cue Biopharma | Oropharyngeal Squamous Cell Carcinoma | 10/27 | 10/27 | | |
NCT04643379: Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma |
|
|
| Active, not recruiting | 2 | 30 | US | Olaparib, Lynparza, Pembrolizumab, Keytruda, Carboplatin, Peripheral blood draw | Washington University School of Medicine, Merck Sharp & Dohme LLC, Joseph Sanchez Foundation | Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma | 11/25 | 11/26 | | |
NCT04331041: Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma |
|
|
| Recruiting | 2 | 42 | US | Adaptive stereotactic body radiation therapy, Adaptive SBRT, Defactinib, VS-6063, PF-04554878, Tumor biopsy, Research blood draw | Washington University School of Medicine, National Cancer Institute (NCI), Verastem, Inc. | Pancreas Cancer, Cancer of the Pancreas, Pancreas Adenocarcinoma | 06/27 | 06/28 | | |
Rambro2, NCT05980000: Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma |
|
|
| Recruiting | 2 | 72 | US | Ramucirumab, Cyramza, Pembrolizumab, MK-3475, Keytruda | Washington University School of Medicine, Eli Lilly and Company | Recurrent Head and Neck Cancer, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma, Metastatic Head and Neck Cancer, HNSCC | 04/28 | 04/31 | | |
NCT05829460: Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia |
|
|
| Not yet recruiting | 2 | 96 | US | Semaglutide, Placebo, LNG-IUD (Progestin), Telemedicine behavioral weight program | Washington University School of Medicine, Novo Nordisk A/S | Endometrial Hyperplasia | 12/29 | 12/31 | | |
NCT05521997: Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer |
|
|
| Not yet recruiting | 2 | 42 | US | Telaglenastat, CB-893, Radiation treatment, Cisplatin | Washington University School of Medicine, National Cancer Institute (NCI), Calithera Biosciences, Inc | Advanced Cervical Carcinoma, Cervical Cancer, Cervix Cancer, Cancer of the Cervix | 04/31 | 04/31 | | |
NCT05616624: ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers |
|
|
| Recruiting | 1/2 | 114 | US | ADI-PEG 20, PEGylated arginine deiminase, Gemcitabine, Gemzar, Docetaxel, Taxotere | Washington University School of Medicine, Polaris Group | Non Small Cell Lung Cancer, Non-small Cell Lung Cancer, Small-cell Lung Cancer, Small Cell Lung Carcinoma | 12/27 | 12/32 | | |
NCT03516708: Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer |
|
|
| Recruiting | 1/2 | 49 | US | Epacadostat, INCB024360, Short-course radiation therapy, SCRT, CAPOX chemotherapy, FOLFOX chemotherapy | Washington University School of Medicine, Incyte Corporation, National Cancer Institute (NCI) | Rectal Cancer | 07/27 | 08/30 | | |
|
NCT04624113: Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma |
|
|
| Terminated | 1 | 13 | US | Tazemetostat, Tazverik, Pembrolizumab, Keytruda | Washington University School of Medicine, Epizyme, Inc. | Head and Neck Squamous Cell Carcinoma | 08/22 | 02/24 | | |
NCT06648434: MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma |
|
|
| Not yet recruiting | 1 | 51 | US | Zunsemetinib, ATI-450, mFOLFIRINOX | Washington University School of Medicine, National Cancer Institute (NCI), Aclaris Therapeutics, Inc. | Metastatic Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Cancer of the Pancreas | 04/27 | 03/30 | | |
NCT06795009: Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer |
|
|
| Not yet recruiting | 1 | 36 | US | Zanzalintinib, XL092, Paclitaxel, Taxol | Washington University School of Medicine, National Cancer Institute (NCI), Exelixis | Uterine Cancer, Endometrial Cancer | 06/29 | 11/34 | | |
NCT05826015: AVB-500 (Batiraxcept) in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer |
|
|
| Withdrawn | 1 | 36 | NA | Paclitaxel, Taxol, Batiraxcept, AVB-500 | Washington University School of Medicine, National Cancer Institute (NCI), Aravive, Inc. | Recurrent High Grade Uterine Cancer | 06/29 | 06/34 | | |
| McKay, Virginia |
| No trials found |
